2024 Q2 Form 10-Q Financial Statement
#000095017024056910 Filed on May 09, 2024
Income Statement
| Concept | 2024 Q2 | 2024 Q1 | 2023 Q1 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Cost Of Revenue | |||
| YoY Change | |||
| Gross Profit | |||
| YoY Change | |||
| Gross Profit Margin | |||
| Selling, General & Admin | $3.533M | $3.742M | $3.470M |
| YoY Change | -1.34% | 7.84% | -7.81% |
| % of Gross Profit | |||
| Research & Development | $5.156M | $4.903M | $4.385M |
| YoY Change | 24.72% | 11.81% | 84.17% |
| % of Gross Profit | |||
| Depreciation & Amortization | $200.0K | $200.0K | $243.0K |
| YoY Change | -17.7% | -17.7% | 1418.75% |
| % of Gross Profit | |||
| Operating Expenses | $8.689M | $8.645M | $7.855M |
| YoY Change | 12.62% | 10.06% | 27.83% |
| Operating Profit | -$8.629M | -$8.562M | -$7.525M |
| YoY Change | 11.85% | 13.78% | 22.46% |
| Interest Expense | $60.00K | $83.00K | |
| YoY Change | |||
| % of Operating Profit | |||
| Other Income/Expense, Net | $0.00 | $0.00 | $330.0K |
| YoY Change | -100.0% | ||
| Pretax Income | -$8.629M | -$8.562M | -$7.525M |
| YoY Change | 11.85% | 13.78% | 22.46% |
| Income Tax | |||
| % Of Pretax Income | |||
| Net Earnings | -$8.629M | -$8.562M | -$7.525M |
| YoY Change | 11.85% | 13.78% | 22.46% |
| Net Earnings / Revenue | |||
| Basic Earnings Per Share | -$0.19 | -$0.20 | -$0.30 |
| Diluted Earnings Per Share | -$0.19 | -$0.20 | -$0.30 |
| COMMON SHARES | |||
| Basic Shares Outstanding | 44.12M | 43.29M | 24.94M |
| Diluted Shares Outstanding | 45.13M | 43.29M | 24.73M |
Balance Sheet
| Concept | 2024 Q2 | 2024 Q1 | 2023 Q1 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $10.22M | $13.02M | $10.86M |
| YoY Change | -39.88% | 19.84% | -66.18% |
| Cash & Equivalents | $10.48M | $13.27M | $11.11M |
| Short-Term Investments | |||
| Other Short-Term Assets | $529.0K | $539.0K | $601.0K |
| YoY Change | 90.97% | -10.32% | -48.5% |
| Inventory | |||
| Prepaid Expenses | |||
| Receivables | |||
| Other Receivables | |||
| Total Short-Term Assets | $12.68M | $15.76M | $14.40M |
| YoY Change | -34.85% | 9.39% | -56.72% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $3.112M | $3.325M | $4.198M |
| YoY Change | -21.75% | -20.8% | 1649.17% |
| Goodwill | |||
| YoY Change | |||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | $320.0K | $576.0K | $255.0K |
| YoY Change | 25.49% | 125.88% | 61.39% |
| Total Long-Term Assets | $9.814M | $9.794M | $10.28M |
| YoY Change | -4.28% | -4.69% | 214.83% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $12.68M | $15.76M | $14.40M |
| Total Long-Term Assets | $9.814M | $9.794M | $10.28M |
| Total Assets | $22.50M | $25.55M | $24.68M |
| YoY Change | -24.3% | 3.53% | -32.46% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $1.444M | $1.413M | $870.0K |
| YoY Change | 146.84% | 62.41% | 57.32% |
| Accrued Expenses | $1.533M | $895.0K | $1.492M |
| YoY Change | -8.42% | -40.01% | 68.78% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | $895.0K | $680.0K | $654.0K |
| YoY Change | 16.99% | 3.98% | 101.23% |
| Total Short-Term Liabilities | $4.759M | $3.844M | $3.748M |
| YoY Change | 25.87% | 2.56% | 81.24% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $526.0K | $351.0K | $664.0K |
| YoY Change | -38.91% | -47.14% | 230.35% |
| Other Long-Term Liabilities | $3.590M | $3.828M | $3.478M |
| YoY Change | 9.55% | 10.06% | 142.54% |
| Total Long-Term Liabilities | $4.116M | $4.179M | $4.142M |
| YoY Change | -0.53% | 0.89% | 153.33% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $4.759M | $3.844M | $3.748M |
| Total Long-Term Liabilities | $4.116M | $4.179M | $4.142M |
| Total Liabilities | $8.875M | $8.023M | $7.890M |
| YoY Change | 12.07% | 1.69% | 113.07% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$108.4M | -$68.74M | |
| YoY Change | 41.8% | 76.99% | |
| Common Stock | $5.000K | $3.000K | |
| YoY Change | 25.0% | 50.0% | |
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $13.62M | $17.53M | $16.79M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $22.50M | $25.55M | $24.68M |
| YoY Change | -24.3% | 3.53% | -32.46% |
Cashflow Statement
| Concept | 2024 Q2 | 2024 Q1 | 2023 Q1 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$8.629M | -$8.562M | -$7.525M |
| YoY Change | 11.85% | 13.78% | 22.46% |
| Depreciation, Depletion And Amortization | $200.0K | $200.0K | $243.0K |
| YoY Change | -17.7% | -17.7% | 1418.75% |
| Cash From Operating Activities | -$6.091M | -$7.919M | -$7.439M |
| YoY Change | 14.11% | 6.45% | 63.17% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | $83.00K | $50.00K | $371.0K |
| YoY Change | 277.27% | -86.52% | -246.64% |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | |||
| YoY Change | |||
| Cash From Investing Activities | -$83.00K | -$71.00K | -$429.0K |
| YoY Change | 277.27% | -83.45% | 69.57% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | |||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | 3.379M | -277.0K | 547.0K |
| YoY Change | -70.6% | -150.64% | -636.27% |
| NET CHANGE | |||
| Cash From Operating Activities | -6.091M | -7.919M | -7.439M |
| Cash From Investing Activities | -83.00K | -71.00K | -429.0K |
| Cash From Financing Activities | 3.379M | -277.0K | 547.0K |
| Net Change In Cash | -2.795M | -8.267M | -7.321M |
| YoY Change | -145.57% | 12.92% | 48.98% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$6.091M | -$7.919M | -$7.439M |
| Capital Expenditures | $83.00K | $50.00K | $371.0K |
| Free Cash Flow | -$6.174M | -$7.969M | -$7.810M |
| YoY Change | 15.19% | 2.04% | 81.37% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2024Q1 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001740279 | |
| CY2024Q1 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q1 | |
| CY2024Q1 | dei |
Amendment Flag
AmendmentFlag
|
false | |
| CY2024Q1 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | |
| CY2024Q1 | dei |
Document Type
DocumentType
|
10-Q | |
| CY2024Q1 | dei |
Document Quarterly Report
DocumentQuarterlyReport
|
true | |
| CY2024Q1 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2024-03-31 | |
| CY2024Q1 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2024 | |
| CY2024Q1 | dei |
Document Transition Report
DocumentTransitionReport
|
false | |
| CY2024Q1 | dei |
Entity File Number
EntityFileNumber
|
001-39692 | |
| CY2024Q1 | dei |
Entity Registrant Name
EntityRegistrantName
|
IN8BIO, INC. | |
| CY2024Q1 | dei |
Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
|
DE | |
| CY2024Q1 | dei |
Entity Tax Identification Number
EntityTaxIdentificationNumber
|
82-5462585 | |
| CY2024Q1 | dei |
Entity Address Address Line1
EntityAddressAddressLine1
|
350 5th Avenue | |
| CY2024Q1 | dei |
Entity Address Address Line2
EntityAddressAddressLine2
|
Suite 5330 | |
| CY2024Q1 | dei |
Entity Address City Or Town
EntityAddressCityOrTown
|
New York | |
| CY2024Q1 | dei |
Entity Address State Or Province
EntityAddressStateOrProvince
|
NY | |
| CY2024Q1 | dei |
Entity Address Postal Zip Code
EntityAddressPostalZipCode
|
10118 | |
| CY2024Q1 | dei |
City Area Code
CityAreaCode
|
646 | |
| CY2024Q1 | dei |
Local Phone Number
LocalPhoneNumber
|
600-6438 | |
| CY2024Q1 | dei |
Security12b Title
Security12bTitle
|
Common Stock, $0.0001 par value per share | |
| CY2024Q1 | dei |
Trading Symbol
TradingSymbol
|
INAB | |
| CY2024Q1 | dei |
Security Exchange Name
SecurityExchangeName
|
NASDAQ | |
| CY2024Q1 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
| CY2024Q1 | dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | |
| CY2024Q1 | dei |
Entity Filer Category
EntityFilerCategory
|
Non-accelerated Filer | |
| CY2024Q1 | dei |
Entity Small Business
EntitySmallBusiness
|
true | |
| CY2024Q1 | dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
true | |
| CY2024Q1 | dei |
Entity Ex Transition Period
EntityExTransitionPeriod
|
false | |
| CY2024Q1 | dei |
Entity Shell Company
EntityShellCompany
|
false | |
| CY2024Q2 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
44123949 | |
| CY2024Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
4903000 | |
| CY2023Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
4385000 | |
| CY2024Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
3742000 | |
| CY2023Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
3470000 | |
| CY2024Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
8645000 | |
| CY2023Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
7855000 | |
| CY2024Q1 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
83000 | |
| CY2023Q1 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
0 | |
| CY2024Q1 | us-gaap |
Other Income
OtherIncome
|
0 | |
| CY2023Q1 | us-gaap |
Other Income
OtherIncome
|
330000 | |
| CY2024Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-8562000 | |
| CY2023Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-7525000 | |
| CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-8562000 | |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-7525000 | |
| CY2024Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.2 | |
| CY2024Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.2 | |
| CY2023Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.3 | |
| CY2023Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.3 | |
| CY2024Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
43287325 | |
| CY2024Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
43287325 | |
| CY2023Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
24732580 | |
| CY2023Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
24732580 | |
| CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
22732000 | |
| CY2023Q1 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
722000 | |
| CY2023Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
859000 | |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-7525000 | |
| CY2023Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
16788000 | |
| CY2023Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
24937000 | |
| CY2024Q1 | us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
89000 | |
| CY2024Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1240000 | |
| CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-8562000 | |
| CY2024Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
17526000 | |
| CY2024Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-8562000 | |
| CY2023Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-7525000 | |
| CY2024Q1 | us-gaap |
Depreciation
Depreciation
|
239000 | |
| CY2023Q1 | us-gaap |
Depreciation
Depreciation
|
243000 | |
| CY2024Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1240000 | |
| CY2023Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
859000 | |
| CY2024Q1 | us-gaap |
Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
|
204000 | |
| CY2023Q1 | us-gaap |
Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
|
188000 | |
| CY2024Q1 | us-gaap |
Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
|
189000 | |
| CY2023Q1 | us-gaap |
Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
|
159000 | |
| CY2024Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-603000 | |
| CY2023Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-510000 | |
| CY2024Q1 | us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
65000 | |
| CY2023Q1 | us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
0 | |
| CY2024Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
489000 | |
| CY2023Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-1035000 | |
| CY2024Q1 | us-gaap |
Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
|
-2060000 | |
| CY2024Q1 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
2740000 | |
| CY2023Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
3343000 | |
| CY2023Q1 | us-gaap |
Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
|
-667000 | |
| CY2024Q1 | inab |
Increase Decrease Short Term Operating Lease Liabilities
IncreaseDecreaseShortTermOperatingLeaseLiabilities
|
37000 | |
| CY2023Q1 | inab |
Increase Decrease Short Term Operating Lease Liabilities
IncreaseDecreaseShortTermOperatingLeaseLiabilities
|
25000 | |
| CY2024Q1 | inab |
Increase Decrease Long Term Operating Lease Liabilities
IncreaseDecreaseLongTermOperatingLeaseLiabilities
|
-233000 | |
| CY2023Q1 | inab |
Increase Decrease Long Term Operating Lease Liabilities
IncreaseDecreaseLongTermOperatingLeaseLiabilities
|
-196000 | |
| CY2024Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-7919000 | |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-7439000 | |
| CY2024Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
50000 | |
| CY2023Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
371000 | |
| CY2024Q1 | inab |
Payments For Construction In Progress
PaymentsForConstructionInProgress
|
21000 | |
| CY2023Q1 | inab |
Payments For Construction In Progress
PaymentsForConstructionInProgress
|
58000 | |
| CY2024Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-71000 | |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-429000 | |
| CY2024Q1 | us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
89000 | |
| CY2023Q1 | us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
0 | |
| CY2024Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
0 | |
| CY2023Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
722000 | |
| CY2024Q1 | us-gaap |
Finance Lease Principal Payments
FinanceLeasePrincipalPayments
|
188000 | |
| CY2023Q1 | us-gaap |
Finance Lease Principal Payments
FinanceLeasePrincipalPayments
|
175000 | |
| CY2024Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-277000 | |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
547000 | |
| CY2024Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-8267000 | |
| CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-7321000 | |
| CY2023Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
21538000 | |
| CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
18434000 | |
| CY2024Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
13271000 | |
| CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
11113000 | |
| CY2024Q1 | us-gaap |
Cash
Cash
|
13015000 | |
| CY2023Q1 | us-gaap |
Cash
Cash
|
10860000 | |
| CY2024Q1 | us-gaap |
Restricted Cash
RestrictedCash
|
256000 | |
| CY2023Q1 | us-gaap |
Restricted Cash
RestrictedCash
|
253000 | |
| CY2024Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
13271000 | |
| CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
11113000 | |
| CY2024Q1 | us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
714000 | |
| CY2023Q1 | us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
0 | |
| CY2024Q1 | inab |
Lease Modification Of Operating Lease Right Of Use Assets And Liabilities
LeaseModificationOfOperatingLeaseRightOfUseAssetsAndLiabilities
|
492000 | |
| CY2023Q1 | inab |
Lease Modification Of Operating Lease Right Of Use Assets And Liabilities
LeaseModificationOfOperatingLeaseRightOfUseAssetsAndLiabilities
|
0 | |
| CY2024Q1 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. ORGANIZATION AND NATURE OF OPERATIONS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Organization and Business</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">IN8bio, Inc. (the "Company") is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell product candidates for solid and liquid tumors. The Company’s lead product candidate, INB-400, is currently in a company-sponsored Phase 2 clinical trial in which autologous, genetically modified gamma-delta T cells will be assessed in newly diagnosed glioblastoma ("GBM") patients at centers across the United States. In addition, the Company has two programs in Phase 1 clinical trials: INB-200, for the treatment of patients with newly diagnosed GBM, and INB-100, for the treatment of patients with hematologic malignancies that are undergoing hematopoietic stem cell transplantation ("HSCT"). In addition, the Company’s DeltEx platform has yielded a broad portfolio of preclinical programs, including INB-300 and INB-500, focused on addressing acute myeloid leukemia ("AML") and other solid and hematological tumor types.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Incysus, Inc. ("Incysus") was a corporation formed in the State of Delaware on November 23, 2015 and Incysus, Ltd. was incorporated in Bermuda on February 8, 2016. Incysus was the wholly owned United States subsidiary of Incysus, Ltd. On May 7, 2018, Incysus, Ltd. reincorporated in the United States in a domestication transaction ("Domestication") in which Incysus, Ltd. converted into a newly formed Delaware corporation, Incysus Therapeutics, Inc. ("Incysus Therapeutics"). On July 24, 2019, Incysus Therapeutics merged with Incysus. Incysus Therapeutics subsequently changed its name to IN8bio, Inc. in August 2020. Following the Domestication in May 2018 and the merging of Incysus Therapeutics and Incysus in July 2019, the Company does not have any subsidiaries to consolidate. The Company is headquartered in New York, New York.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Liquidity and Going Concern</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To date, the Company has funded its operations primarily with proceeds from various public and private offerings of its common stock, preferred stock and warrants. The Company has incurred recurring losses and negative operating cash flows since its inception, including net losses of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;">8.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the three months ended March 31, 2024 and 2023, respectively. As of March 31, 2024, the Company had an accumulated deficit of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;">99.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has not yet generated product sales and as a result has experienced operating losses since inception. The Company expects to incur additional losses in the future as it advances its product candidates through clinical trials, seeks to expand its product candidate portfolio through developing additional product candidates, grows its clinical, regulatory and quality capabilities, and incurs costs associated with operating as a public company. Based on the Company’s business strategy, its existing cash of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;">13.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2024 will only fund the Company’s projected operating expenses and capital expenditure requirements into January 2025. Accordingly, there is substantial doubt about the Company’s ability to continue to operate as a going concern for a period of 12 months from the date of issuance of these condensed financial statements. To continue to fund the operations of the Company beyond this time period, management has developed plans, which primarily consist of raising additional capital through some combination of equity and/or debt offerings, including through at-the-market program ("ATM") offerings and private placements of securities, and identifying strategic collaborations, licensing or other arrangements to support development of the Company’s product candidates. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Through May 2, 2024, the Company sold an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">856,624</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its common stock under the ATM program, resulting in net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million after deducting underwriting discounts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the Company may receive an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">14.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in aggregate proceeds if the holders of the Series A ordinary warrants exercise their warrants pursuant to the mandatory exercise feature, which is triggered upon the Company's public announcement of INB-100 data for the 10 currently enrolled patients, should they remain alive and evaluable, covering a period of at least 11 months of long-term follow-up for each patient, along with certain stock price and trading volume requirements. Further, if not otherwise redeemed by the Company, the Company may also receive aggregate proceeds of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">17.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million from the exercise of its outstanding Series B ordinary warrants. There is no assurance, however, that the Company will receive any additional proceeds from these warrants or that any additional financing or any revenue-generating collaboration will be available when needed, that management of the Company will be able to obtain financing or enter into a collaboration on terms acceptable to the Company, or that any additional financing or revenue generated through third party collaborations will be sufficient to fund our operations through this time period. If additional capital is not available, the Company will have to significantly delay, scale back or discontinue research and development programs or future commercialization efforts. The actual amount of cash that the Company will need to operate is subject to many factors. The accompanying condensed financial statements have been prepared on the basis that the Company will continue as a going concern and do not include adjustments that might result from the outcome of this uncertainty</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p> | |
| CY2024Q1 | us-gaap |
Cash
Cash
|
13000000 | |
| CY2024Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of condensed financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the condensed financial statements, and the reported amounts of expenses during the reporting periods presented. Such estimates and assumptions are used for, but are not limited to, the accrual of research and development expenses, deferred tax assets and liabilities and the related valuation allowance, stock-based compensation, the useful lives of property and equipment and the valuation of warrants. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span></p> | |
| CY2024Q1 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially expose the Company to significant concentrations of credit risk consist primarily of cash. All of the Company’s cash and restricted cash is deposited in accounts with major financial institutions. Such deposits are in excess of the federally insured limits.</span></p> | |
| CY2024Q1 | inab |
Prepaid Research And Development
PrepaidResearchAndDevelopment
|
1752000 | |
| CY2023Q4 | inab |
Prepaid Research And Development
PrepaidResearchAndDevelopment
|
2283000 | |
| CY2024Q1 | us-gaap |
Prepaid Insurance
PrepaidInsurance
|
449000 | |
| CY2023Q4 | us-gaap |
Prepaid Insurance
PrepaidInsurance
|
790000 | |
| CY2024Q1 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
539000 | |
| CY2023Q4 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
270000 | |
| CY2024Q1 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
1522000 | |
| CY2023Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
1283000 | |
| CY2024Q1 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
3325000 | |
| CY2023Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
3514000 | |
| CY2024Q1 | us-gaap |
Depreciation
Depreciation
|
200000 | |
| CY2023Q1 | us-gaap |
Depreciation
Depreciation
|
200000 | |
| CY2024Q1 | us-gaap |
Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
|
203000 | |
| CY2023Q1 | us-gaap |
Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
|
182000 | |
| CY2024Q1 | us-gaap |
Construction In Progress Gross
ConstructionInProgressGross
|
203000 | |
| CY2023Q1 | us-gaap |
Construction In Progress Gross
ConstructionInProgressGross
|
182000 | |
| CY2024Q1 | inab |
Accrued Clinical Trials
AccruedClinicalTrials
|
153000 | |
| CY2023Q4 | inab |
Accrued Clinical Trials
AccruedClinicalTrials
|
598000 | |
| CY2024Q1 | inab |
Accrued Compensation
AccruedCompensation
|
480000 | |
| CY2023Q4 | inab |
Accrued Compensation
AccruedCompensation
|
1673000 | |
| CY2024Q1 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
79000 | |
| CY2023Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
306000 | |
| CY2024Q1 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
183000 | |
| CY2023Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
378000 | |
| CY2024Q1 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
895000 | |
| CY2023Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
2955000 | |
| CY2024Q1 | us-gaap |
Capital Units Authorized
CapitalUnitsAuthorized
|
500000000 | |
| CY2024Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
| CY2024Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
490000000 | |
| CY2024Q1 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | |
| CY2023Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
6695933 | |
| CY2023Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
3.52 | |
| CY2023 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P8Y3M25D | |
| CY2023Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
361000 | |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
1690675 | |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
1.24 | |
| CY2024Q1 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
0 | |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
0 | |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
50335 | |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
4.43 | |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
8336273 | |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
3.05 | |
| CY2024Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P8Y5M26D | |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
40000 | |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
2797539 | |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
5.04 | |
| CY2024Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P7Y5M12D | |
| CY2024Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
|
17000 | |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
|
5538734 | |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
|
2.05 | |
| CY2024Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
|
P9Y7D | |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
|
23000 | |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
1.24 | |
| CY2023Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
2 | |
| CY2023Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.9191 | |
| CY2024Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P6Y29D | |
| CY2023Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P6Y29D | |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
|
0.0398 | |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
|
0.0416 | |
| CY2023Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
3870924 | |
| CY2023Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0399 | |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | |
| CY2023Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | |
| CY2024Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1240000 | |
| CY2023Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
859000 | |
| CY2024Q1 | us-gaap |
Employee Service Share Based Compensation Tax Benefit From Exercise Of Stock Options
EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
|
0 | |
| CY2023Q1 | us-gaap |
Employee Service Share Based Compensation Tax Benefit From Exercise Of Stock Options
EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
|
0 | |
| CY2024Q1 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
|
7500000 | |
| CY2024Q1 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P2Y7M17D | |
| CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-8562000 | |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-7525000 | |
| CY2024Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.2 | |
| CY2024Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.2 | |
| CY2023Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.3 | |
| CY2023Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.3 | |
| CY2024Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
43287325 | |
| CY2024Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
43287325 | |
| CY2023Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
24732580 | |
| CY2023Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
24732580 | |
| CY2024Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
31929683 | |
| CY2024Q1 | inab |
Royalty Term
RoyaltyTerm
|
P15Y | |
| CY2024Q1 | inab |
Amortization Of Finance Right Of Use Assets
AmortizationOfFinanceRightOfUseAssets
|
204000 | |
| CY2023Q1 | inab |
Amortization Of Finance Right Of Use Assets
AmortizationOfFinanceRightOfUseAssets
|
149000 | |
| CY2024Q1 | us-gaap |
Finance Lease Interest Expense
FinanceLeaseInterestExpense
|
27000 | |
| CY2023Q1 | us-gaap |
Finance Lease Interest Expense
FinanceLeaseInterestExpense
|
14000 | |
| CY2024Q1 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
304000 | |
| CY2023Q1 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
112000 | |
| CY2024Q1 | us-gaap |
Short Term Lease Cost
ShortTermLeaseCost
|
83000 | |
| CY2023Q1 | us-gaap |
Short Term Lease Cost
ShortTermLeaseCost
|
105000 | |
| CY2024Q1 | us-gaap |
Variable Lease Cost
VariableLeaseCost
|
24000 | |
| CY2023Q1 | us-gaap |
Variable Lease Cost
VariableLeaseCost
|
0 | |
| CY2024Q1 | us-gaap |
Lease Cost
LeaseCost
|
642000 | |
| CY2023Q1 | us-gaap |
Lease Cost
LeaseCost
|
380000 | |
| CY2024Q1 | inab |
Cash Paid For Amounts Included In Finance Leases
CashPaidForAmountsIncludedInFinanceLeases
|
27000 | |
| CY2024Q1 | inab |
Cash Paid For Amounts Included In Operating Leases
CashPaidForAmountsIncludedInOperatingLeases
|
310000 | |
| CY2024Q1 | us-gaap |
Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
|
P1Y6M25D | |
| CY2024Q1 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P4Y4M9D | |
| CY2024Q1 | us-gaap |
Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
|
0.095 | |
| CY2024Q1 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.127 | |
| CY2024Q1 | us-gaap |
Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
|
552000 | |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
|
1051000 | |
| CY2024Q1 | us-gaap |
Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
|
501000 | |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
1401000 | |
| CY2024Q1 | us-gaap |
Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
|
52000 | |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
1416000 | |
| CY2024Q1 | us-gaap |
Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
|
0 | |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
1224000 | |
| CY2024Q1 | us-gaap |
Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
|
0 | |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
|
891000 | |
| CY2024Q1 | inab |
Finance Lease Liability Payments Due After Year Four
FinanceLeaseLiabilityPaymentsDueAfterYearFour
|
0 | |
| CY2024Q1 | inab |
Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
|
120000 | |
| CY2024Q1 | us-gaap |
Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
|
1105000 | |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
6103000 | |
| CY2024Q1 | us-gaap |
Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
|
74000 | |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
1419000 | |
| CY2024Q1 | us-gaap |
Finance Lease Liability
FinanceLeaseLiability
|
1031000 | |
| CY2024Q1 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
4684000 | |
| CY2024Q1 | us-gaap |
Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
|
680000 | |
| CY2024Q1 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
856000 | |
| CY2024Q1 | us-gaap |
Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
|
351000 | |
| CY2024Q1 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
3828000 | |
| CY2024Q1 | ecd |
Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
|
false | |
| CY2024Q1 | ecd |
Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
|
false | |
| CY2024Q1 | inab |
Rule10 B51 Arrmodifiedflag
Rule10B51Arrmodifiedflag
|
false | |
| CY2024Q1 | inab |
Nonrule10 B51 Arrmodifiedflag
Nonrule10B51Arrmodifiedflag
|
false | |
| CY2024Q1 | ecd |
Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
|
false | |
| CY2024Q1 | ecd |
Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
|
false |
